Rep. Daniel S. Goldman sold CareDx (CDNA)
Rep. Daniel S. Goldman (D-NY-10) · $1K–$15K · traded Mar 6, 2023
- Transaction
- Sold
- Amount
- $1K–$15K
- Owner
- Not stated
- Traded
- Mar 6, 2023
- Disclosed
- Apr 17, 2023
- Days to disclose
- 42
- Asset type
- Stock
- As filed
- CareDx, Inc.
- Industry
- Medical - Diagnostics & Research · Healthcare
Other trades in this filing
All of Goldman's trades →- Apr 17, 2023$1K–$15K
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$50K–$100K
Sold VONOVIA SE ADR CMN (VONOY)
$50K–$100K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$15K–$50K
Bought VOLKSWAGEN AKTIENGESELLSCHAFT ADR CMN (VWAPY)
$15K–$50K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$15K–$50K
Sold (partial) Vodafone Group Public Limited Company VOD
$15K–$50K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
Bought VAT GROUP AG ADR CMN (VACNY)
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
Sold (partial) UPM-KYMMENE OYJ ADR CMN (UPMMY)
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
Bought Swedbank AB (publ) SWDBY
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
Bought Sumitomo Mitsui Financial Group SMFG
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
Sold SOMPO JAPAN NIPPONKOA HLDGS IN ADR CMN (SMPNY)
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$15K–$50K
$15K–$50K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$15K–$50K
$15K–$50K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
Sold (partial) Shiseido Company, Limited SSDOY
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$15K–$50K
Bought SALMAR ASA ADR CMN (SALRY)
$15K–$50K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
Company context for CDNA
Recent records for the company. These may have been published before or after this trade; compare the dates before drawing a connection.
CDNA: second_quarter 2026 lobbying report
Medicare coverage of molecular testing for solid organ allograft rejection. Medicare payment of clinical laboratory tests. Implementation of Sec 216 of the Protecting Access to Medicare Act of 2014 (PL 113-93) and RESULTS Act (H.R.5269). Prior authorization of molecular tests.
Public: Oct 20, 2026, 4:36 PM EDTOriginal source ↗CDNA: third_quarter 2026 lobbying report
-Medicare coverage of molecular testing for solid organ allograft rejection -Medicare payment of clinical laboratory tests; implementation of Sec 216 of the Protecting Access to Medicare Act of 2014 (PL 113-93) -Prior authorization of molecular tests Living Donor Protection Act (LDPA) S1522, HR4582,HR4583
Public: Oct 13, 2026, 3:56 PM EDTOriginal source ↗CDNA: second_quarter 2026 lobbying report
Medicare coverage of molecular testing for solid organ allograft rejection. Medicare payment of clinical laboratory tests. Implementation of Sec 216 of the Protecting Access to Medicare Act of 2014 (PL 113-93) and RESULTS Act (H.R.5269). Prior authorization of molecular tests.
Public: Jul 20, 2026, 7:30 PM EDTOriginal source ↗
From a periodic transaction report filed under the STOCK Act. Amounts are the ranges members report. Nothing here is investment advice.